Melanoma of the eye (ocular/uveal melanoma) is an uncommon type of cancer that is associated
with a high mortality. It usually disseminates rapidly throughout the body, most commonly to
the liver and lungs. In this study a combination therapy with immunotherapy (ipilimumab with
nivolumab) and chemotherapy (melphalan) will be assessed for the treatment of disseminated
uveal melanoma. Melphalan will be administered selectively to the liver via percutaneous
hepatic perfusion, limiting the systemic effect of chemotherapy. With this treatment
combination we aim to find a treatment for disseminated uveal melanoma, both in the liver as
in the other organs.